Effects of vatinoxan on cardiorespiratory function and gastrointestinal motility during constant-rate medetomidine infusion in standing horses.
Authors: Tapio H, Raekallio M R, Mykkänen A, Männikkö S, Scheinin M, Bennett R C, Vainio O
Journal: Equine veterinary journal
Summary
# Editorial Summary: Vatinoxan as an Adjunct to Medetomidine in Standing Horses Medetomidine's α₂-adrenergic effects produce profound cardiovascular depression and gastrointestinal stasis in horses, limiting its clinical utility during prolonged sedation. This randomised, blinded cross-over trial evaluated whether vatinoxan, a peripheral α₂-antagonist, could mitigate these unwanted effects whilst maintaining sedation in six healthy standing horses receiving medetomidine as a 7 μg/kg bolus followed by constant-rate infusion at 3.5 μg/kg/h for 60 minutes. Vatinoxan administration (140 μg/kg) significantly improved haemodynamic stability: at 10 minutes, heart rate increased from 26 to 31 beats/minute and mean arterial pressure decreased from 129 to 103 mmHg, whilst cardiac index improved and systemic vascular resistance reduced. Notably, gastrointestinal borborygmi—substantially suppressed by medetomidine alone—were significantly preserved with vatinoxan co-administration, an important consideration for colic risk during standing procedures. Sedation depth was only marginally reduced during the first 20 minutes, suggesting vatinoxan's peripheral selectivity preserved the desired central nervous system effects. For practitioners, these findings suggest vatinoxan warrants investigation as an adjunct to medetomidine CRI in clinical settings, potentially enabling safer longer-duration standing sedation with reduced cardiovascular and gastrointestinal compromise, though further work in stimulated or surgical contexts would strengthen clinical applicability.
Read the full abstract on PubMed
Practical Takeaways
- •Vatinoxan can be used as an adjunct to medetomidine in standing horses to reduce unwanted cardiovascular depression and gastrointestinal stasis while maintaining adequate sedation
- •Addition of vatinoxan (140 μg/kg IV) with medetomidine loading dose offers a practical strategy to improve tolerance of alpha-2 agonist sedation in clinical settings
- •Consider vatinoxan when medetomidine-induced bradycardia, hypertension, or ileus are concerns, though full sedation may be slightly reduced in the first 20 minutes
Key Findings
- •Vatinoxan significantly improved cardiovascular function during medetomidine CRI, with higher heart rate (31±5 vs 26±2 bpm at 10 min, P=0.04) and lower mean arterial pressure (103±13 vs 129±15 mmHg, P<0.001)
- •Gastrointestinal motility (borborygmi) reduction caused by medetomidine was significantly attenuated by vatinoxan co-administration (P<0.001)
- •Sedation scores were significantly reduced with vatinoxan during the first 20 minutes (4.5±1.5 vs 6.8±0.8 at 10 min, P=0.001)
- •Plasma dexmedetomidine concentration was significantly lower in the presence of vatinoxan (P=0.01)